After its depression candidate failed a phase 3 trial and disappointed analysts, Neumora is shaking up its leadership team.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback